CA 27.29 - Breast Cancer
A search of UptoDate provided a reference to "American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer" (PMID: 17954709.)
There is not much in the way of prospective studies on CA27.29, probably because it measures the same antigen as CA15-3 (MUC-1). At any rate, as a result of a systematic review of the literature, the ASCO 2007 Update concludes that although some of the studies show some value of these markers in detecting recurrence, there is no data to show "clinical benefit in terms of disease-free survival, overall survival, quality of life, toxicity, or cost-effectiveness."
Nicolini A, Tartarelli G, Carpi A, et al: Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases. BMC Cancer 6:269, 2006.
PMID: 17116247
Follow-up study of 268 breast cancer patients in clinical remission at the beginning of the study.
